ZEISS-MEL-80-EXCIMER-LASER – ZEISS camera lenses were recognized as the world’s highest quality after their introduction in the 1800s. In the late 1980s, ZEISS optical lenses became the technology of choice for the developers of vision correction lasers.
Carl Zeiss Meditec has been a refractive surgery pioneer for more than 20 years.
Combining its finest optics with the most advanced excimer laser technology available, Carl Zeiss Meditec brings you laser vision correction with a fourth-generation laser platform, the MEL 80.”MEL” stands for “Meditec Excimer Laser.”
The MEL 80 is a fourth generation Carl Zeiss excimer laser platform, taking vision correction to a new level. By reshaping the human cornea to its most natural shape during treatment, your vision can now be similar to the quality of lenses on which Carl Zeiss has built its reputation. The goal is to deliver high resolution vision with a custom treatment unique to your prescription. Carl Zeiss engineers created this advanced vision correcting technique using the latest wavefront techology innovations. This scientific method takes into consideration not only the clarity of vision from the shape of your eye, but it also treats other irregularities within your eye that may prevent you from having a higher quality of vision. One of the fastest excimer lasers in the world, your treatment is completed within seconds.
Carl Zeiss commitment to delivering superior optics with laser precision. The MEL 80 is yet another powerful example of this commitment, delivering high performance and exceptional visual results-all day and all night.
- 93% of patients were corrected at 6 months to 20/20 or better visual acuity
- 41% were corrected to 20/12.5 or better 6 months after treatment
- MEL 80’s aberration-optimized algorithms minimize spherical aberration that causes night vision problems
Precise Pulse Technology safely and accurately controls every single laser pulse from beginning to end. Using Zeiss PrecisePulse™ Technology, every beam of the laser is precisely placed on the cornea while an active eyetracker with an ultra-rapid infrared camera tracks the eye’s position 250 times per second. The MEL 80 eyetracker doesn’t use just one landmark on the eye, it uses two, which is an important feature for exact registration and laser alignment. If your eye ever moves out of the treatment range, the laser treatment pauses until the eye is realigned.
The MEL 80 excimer laser offers high performance considers patient comfort. It safely and significantly reduces treatment time, providing benefits for both surgeon and patient:
- Reduced stromal bed exposure minimizes dehydration and accelerates regeneration
- A thermally-optimized laser firing pattern protects the stroma despite high ablation speed
- The ability to create a precise, aspheric corneal curvature
- Patients need to concentrate on the fixation light for only a few seconds
With the tiniest spot size and its Gaussian beam profile the MEL 80 produces matchless quality in corneal ablation – exact, even and protective of the surrounding tissue. Even in complex ablation procedures, the large overlap of the laser spot zones yields very smooth surfaces.
Two specially optimized ablation profiles help you produce excellent results:
- ASA (Aberration Smart Ablation) – tried and tested strongly aspherical profiles, optimized for “mesopic vision”
- TSA (Tissue Saving Algorithm) – the conservative tissue-saving alternative with lower asphericity for re-treatment and thin corneas
The MEL 80 helps you significantly reduce the duration of treatment. This has the following benefits:
- The stromal bed is only open for a short period; this prevents dehydration and speeds up the regeneration process.
- The thermally-optimized distribution of the laser firing pattern protects the stroma – despite the high ablation speed.
- Patients’ stress is relieved; they only need to concentrate for a few seconds on the fixation light.
- The exceptionally fast ablation time reduces procedure time for greater patient comfort.
- Very small 0.7 mm spot permits the finest correction without losing the benefits of a small ablation.
- An active eyetracker with excellent feedback times and an IR camera catching both pupil and limbus provides exact positioning during the laser treatment.
- Two specially optimized ablation profiles to choose from
The Carl Zeiss Meditec MEL 80 Excimer Laser System is indicated for use in primary Laser Assisted In Situ Keratomileusis (LASIK) for:
- For the reduction or elimination of myopia of less than or equal to -7.0 D with or without refractive astigmatism of less than or equal to -3.0 D;
- In subjects with documentation of stable manifest refraction over the prior year;
- In subjects who are 21 years of age or older.
The objectives of this study was to evaluate the safety and effectiveness of the Meditec MEL 80 Excimer Laser System for the reduction or elimination of myopia of less than or equal to -10.00 D, and astigmatism less than or equal to -3.50 D at the spectacle plane, when used as part of the LASIK surgical procedure.
At three months, the overall quality of vision was rated highly, with 99.4% of patients indicating that there was an improvement, while only 0.6% indicated that there was no improvement; 94.4% would elect to have the surgery again; 98.3% reported being satisfied, while 0.6% were neutral and 1.1% were dissatisfied.
Response: | At 3 Months: | At 6 Months: |
No Improvement | 0.6% | 0.6% |
Slight Improvement | 1.1% | 0% |
Moderate Improvement | 1.1% | 1.7% |
Marked Improvement | 14.4% | 16.3% |
Extreme Improvement | 82.8% | 81.5% |
No | 1.1% | 2.2% |
Yes | 94.4% | 94.4% |
Unsure | 4.4% | 3.4% |
Very Satisfied | 90.6% | 88.8% |
Moderately Satisfied | 7.8% | 8.4% |
Neutral | 0.6% | 1.7% |
Dissatisfied | 1.1% | 0.6% |
Very Dissatisfied | 0.0% | 0.6% |
Conclusions Drawn From The Clinical Study:
The data in this application provides reasonable assurance that the device is safe and effective when used in accordance with the directions for use. The FDA issued its approval of the Meditec MEL 80 Excimer Laser System on August 15, 2006
No comments:
Post a Comment